Search Results

Drug interactions involving the new second- and third-generation antiepileptic drugs

Authors: Johannessen Landmark, Cecilie; Patsalos, Philip N

Source: Expert Review of Neurotherapeutics, Volume 10, Number 1, January 2010 , pp. 119-140(22)

Publisher: Expert Reviews

Role of Antiepileptic Drugs as Preventive Agents for Migraine

Authors: Vikelis, Michail; Rapoport, Alan M.

Source: CNS Drugs, Volume 24, Number 1, 1 January 2010 , pp. 21-33(13)

Publisher: Adis International

Association between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations

Authors: Hamoda, Hesham M; Guild, Danielle J; Gumlak, Sarah; Travers, Brian H; Gonzalez-Heydrich, Joseph

Source: Expert Review of Neurotherapeutics, Volume 9, Number 12, December 2009 , pp. 1747-1754(8)

Publisher: Expert Reviews

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval

Authors: Tolman, Justin A; Faulkner, Michele A

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 18, December 2009 , pp. 3077-3089(13)

Publisher: Informa Healthcare

MHRA November update

Source: Reactions, Volume 1, Number 1278, 2009-11-14 , pp. 3-3(1)

Publisher: Adis International

Visual Field Loss in Patients with Refractory Partial Epilepsy Treated with Vigabatrin: Final Results from an Open-Label, Observational, Multicentre Study

Authors: Wild, John M.; Chiron, Catherine; Ahn, Hyosook; Baulac, Michel; Bursztyn, Joseph; Gandolfo, Enrico; Goldberg, Ivan; >Francisco Javier Goñi,; Mercier, Florence; Nordmann, Jean-Philippe; Safran, Avinoam B.; Schiefer, Ulrich; Perucca, Emilio

Source: CNS Drugs, Volume 23, Number 11, 1 November 2009 , pp. 965-982(18)

Publisher: Adis International

Evaluating Risks for Vigabatrin Treatment

Author: Krauss, Gregory L.

Source: Epilepsy Currents, Volume 9, Number 5, September/October 2009 , pp. 125-129(5)

Publisher: Blackwell Publishing

Vigabatrin's Complicated Journey—To Be or Not to Be?

Source: Epilepsy Currents, Volume 9, Number 5, September/October 2009 , pp. 130-132(3)

Publisher: Blackwell Publishing

Sabril [vigabatrin] has been approved by the US FDA, with a boxed warning with regard to vision damage.

Source: Reactions, Volume 1, Number 1267, 2009-08-29 , pp. 3-3(1)

Publisher: Adis International

Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life?

Author: Riikonen, Raili

Source: Epilepsia, Volume 50, Number 8, August 2009 , pp. 2005-2006(2)

Publisher: Blackwell Publishing

Vigabatrin therapy in infantile spasms: Solving one problem and inducing another?

Authors: Wohlrab, Gabriele; Leiba, Hana; Kästle, Rebekka; Ramelli, Gianpaolo; Schmitt-Mechelke, Thomas; Schmitt, Bernhard; Landau, Klara

Source: Epilepsia, Volume 50, Number 8, August 2009 , pp. 2006-2008(3)

Publisher: Blackwell Publishing

Symptomatic management of the neurological, renal and pulmonary manifestations of tuberous sclerosis is essential

Author: Adis International Limited,

Source: Drugs & Therapy Perspectives, Volume 25, Number 6, June 2009 , pp. 13-15(3)

Publisher: Adis International

Vigabatrin: Cerebral MRI abnormalities in infants: 8 case reports

Source: Reactions, Volume 1, Numbers 1247-1248, 2009-04-11 , pp. 34-34(1)

Publisher: Adis International

Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat

Authors: Ferraro, Giuseppe; Sardo, Pierangelo

Source: Epilepsia, Volume 50, Number 4, April 2009 , pp. 721-730(10)

Publisher: Blackwell Publishing

Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin - CME questions

Authors: Cohen-Sadan, S.; Kramer, U.; Ben-Zeev, B.; Lahat, E.; Sahar, E.; Nevo, Y.; Eidlitz, T.; Zeharia, A.; Kivity, S.; Goldberg-Stern, H.

Source: European Journal of Neurology, Volume 16, Number 5, May 2009 , pp. 555-555(1)

Publisher: Blackwell Publishing

Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin

Authors: Cohen-Sadan, S.; Kramer, U.; Ben-Zeev, B.; Lahat, E.; Sahar, E.; Nevo, Y.; Eidlitz, T.; Zeharia, A.; Kivity, S.; Goldberg-Stern, H.

Source: European Journal of Neurology, Volume 16, Number 4, April 2009 , pp. 482-487(6)

Publisher: Blackwell Publishing

Vigabatrin: Asymptomatic visual field loss: 2 case reports

Source: Reactions, Volume 1, Number 1240, 2009-02-21 , pp. 41-41(1)

Publisher: Adis International

Antiepileptic drugs/paracetamol: Suicide, suicidal ideation and other CNS disorders (first report of anger with ethosuximide, and of nightmares with pregabalin): 15 case reports

Source: Reactions, Volume 1, Number 1241, 2009-02-28 , pp. 9-10(2)

Publisher: Adis International

Vigabatrin: 2008 Update

Authors: James Willmore, L.; Abelson, Mark B.; Ben-Menachem, Elinor; Pellock, John M.; Donald Shields, W.

Source: Epilepsia, Volume 50, Number 2, February 2009 , pp. 163-173(11)

Publisher: Blackwell Publishing

Vigabatrin extracellular pharmacokinetics and concurrent γ-aminobutyric acid neurotransmitter effects in rat frontal cortex and hippocampus using microdialysis

Authors: Tong, Xin; Ratnaraj, Neville; Patsalos, Philip N.

Source: Epilepsia, Volume 50, Number 2, February 2009 , pp. 174-183(10)

Publisher: Blackwell Publishing